01 October 2005
Assessment of motoneuron death during development following neonatal nerve crush and Mg2+ treatment.
Dorothea Kapoukranidou, Nikolaos Gougoulias, Athanasios Hatzisotiriou, Dimitra Fardi, Maria Albani, Ioannis KalpidisMed Sci Monit 2005; 11(10): BR373-379 :: ID: 430298
Abstract
BACKGROUND: Sciatic nerve injury in neonatal rats impairs muscle recovery and significantly reduces the number of surviving motoneurons. We examined the rate of motoneuron death after sciatic nerve crush in neonatal rats, as well as the neuroprotective effect of systemic MgSO4 administration, by assessing the number of horseradish peroxidase -labelled motoneurons in the spinal cord ventral horn, after injecting EDL and TA muscles. MATERIAL/METHODS: Left sciatic nerve crush was performed on the 2nd postnatal day. MgSO4 (0.05 ml of 1 M solution/10 g body weight) was administered subcutaneously, daily for twelve days. Animals were examined for the number of motoneurons of EDL and TA muscles, in the spinal cord ventral horns at 14, 21, and 28 days postnatally (P) and adulthood. 24 h to 48 h after intramuscular HRP injection, the animals were perfused transcardially with a fixative containing glutaraldehyde. Serial sections of the spinal cords were cut and processed for Hanker-Yates staining, and the number of labeled motoneurons was measured under a camera lucida. RESULTS: Nerve crush resulted in 37% motoneuron survival at P14, 33% at P21, 28% at P28 and 21% in adult rats. Following MgSO4 administration motoneuron survival rates of 51%, 47%, 44% and 39% were observed respectively, for the different age groups. The values obtained in magnesium-treated rats proved to be significantly different (p
Keywords: Cell Death - drug effects, Animals, Newborn, Magnesium Sulfate - pharmacology, Motor Neurons - drug effects, Nerve Crush, Rats, Wistar, Sciatic Nerve - injuries
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952